Review
Endocrinology & Metabolism
Sergio Di Molfetta, Andrea Dotto, Giuseppe Fanciulli, Tullio Florio, Tiziana Feola, Annamaria Colao, Antongiulio Faggiano
Summary: Medullary thyroid carcinoma is a rare neuroendocrine neoplasm that usually requires surgery for treatment. Recent interest in immune checkpoint inhibitors has sparked hope for new treatment options for patients with this type of cancer.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Daqi Zhang, Mingyu Yang, Xin Zhang, Cheng Wang, Kunlin Li, Hongbo Wang, Hao Chi, Chengqiu Sui, Gianlorenzo Dionigi, Hui Sun
Summary: This study presents a rare case series of synchronous occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same thyroid gland. The synchronous MTC/PTC were classified into 4 subtypes and the clinical and pathological aspects as well as the results were presented.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ming-Wei Kao, Yao-Hung Kuo, Kun-Chou Hsieh, Ching-Tai Lee, Shih-Chi Wu, Wen-Chi Yang
Summary: For patients with unresectable esophageal squamous cell carcinoma (SCC), combination therapy of nivolumab and chemotherapy demonstrates a better overall response rate and longer overall survival compared to chemotherapy alone or with radiotherapy. The expression of PD-L1 in esophageal cancer is associated with poor prognosis. Nivolumab with chemotherapy provides a more effective treatment option with fewer adverse effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Zhanwei Wang, Dionyssios Katsaros, Junlong Wang, Nicholetta Biglio, Brenda Y. Hernandez, Peiwen Fei, Lingeng Lu, Harvey Risch, Herbert Yu
Summary: Host immunity involves various immune cells working together to achieve balanced immune response. By analyzing immune cell clusters related to breast cancer progression, our study suggests that different immune cell clusters may indicate distinct immune responses to tumor growth, which has potential implications for disease management.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Caitlin O. Caperton, Lee Ann Jolly, Nicole Massoll, Andrew J. Bauer, Aime T. Franco
Summary: Advancements in thyroid cancer research rely on access to experimental models for laboratory investigation. The development and characterization of three novel follicular thyroid cancer (FTC) cell lines from relevant animal models have been demonstrated. These cell lines exhibit potential for in vitro applications and transplantation into immunocompetent hosts, providing insights into the heterogeneity of pathogenesis in thyroid cancer.
Article
Dermatology
Vasiliki A. Nikolaou, Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freites-Martinez, Konstantinos Lallas, Maria Concetta Romano, Chrysa Oikonomou, Michela Starace, Meletios A. Dimopoulos, Athanassios Kyrgidis, Elizabeth Lazaridou, Priscila Giavedoni, Maria Carmela Annunziata, Ketty Peris, Maria Echeverria, Emilio Lopez-Tujillo, Konstandinos Syrigos, Chryssoula Papageorgiou, Sebastian Podlipnik, Gabriella Fabbrocini, Ana C. Torre, Christina Kemanetzi, Lorena Villa-Crespo, Aimilios Lallas, Alexander J. Stratigos, Vincent Sibaud
Summary: The study demonstrates that ICI-related skin toxicities do not share a single pattern and may depend on several factors, including the specific drug administered and the underlying malignancy. Patients with macular rash, vitiligo, or multiple skin toxicities were more frequently treated with ICIs for melanoma rather than non-small cell lung cancer. The combination of ICI and chemotherapy compared to ICI monotherapy was associated with a lower incidence of psoriatic rash, lichenoid, and eczematous reactions in patients, compared to those with pruritic rash.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Oncology
Zenovia Gonzalez, Lindsey Carlsen, Wafik S. El-Deiry
Summary: Colorectal cancer is the third most diagnosed and deadliest cancer globally. Most metastatic colorectal cancer patients have microsatellite stable tumors that do not respond to immune checkpoint inhibitors. The results of the 2022 MAYA clinical trial suggest that combining the DNA-damaging agent temozolomide with immune checkpoint inhibitors can sensitize certain colorectal cancer patients to treatment. The study aimed to determine the effects of adding immune checkpoint inhibitors to temozolomide on colorectal cancer cells and the role of MGMT in this response.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Review
Oncology
Xin Zhao, Fengwei Gao, Jie Yang, Hua Fan, Qingyun Xie, Kangyi Jiang, Jie Gong, Benjian Gao, Qian Yang, Zehua Lei
Summary: This study evaluated the risks of common adverse events associated with the combinatorial regimen of ipilimumab and nivolumab. Meta-analysis results showed that the risks of any grade and grade >= 3 adverse events in the combinatorial treatment were 90.42% and 46.46%, respectively. The study also classified 19 common adverse events and further analyzed the impacts of different cancer types and treatment schemes on adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ulrich Sterz, Matthias Grube, Wolfgang Herr, Karin Menhart, Christina Wendl, Martin Vogelhuber
Summary: This case report describes a 37-year-old patient with metastatic advanced osteosarcoma who achieved a deep remission of disease through immunotherapy with ipilimumab and nivolumab. Despite a three-month interruption of immunotherapy due to therapy-related pneumonitis, the remission of tumor manifestations continued. Further investigation is needed to determine if high PD-L1 expression, as seen in this patient, can predict response to immunotherapy in osteosarcoma.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P. Moy, Stephen W. Dusza, Allison Gordon, Elena C. Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A. Quigley, Paul Chapman, Mario E. Lacouture, Alina Markova
Summary: Immune checkpoint inhibitors (ICI) can effectively target cancer cells, but they may also cause immune-related cutaneous adverse events (ircAEs) in a significant number of patients. This study examined the use of dupilumab for treating ICI-associated ircAEs and found that 87% of patients responded to the treatment, with 44.1% achieving complete resolution of the adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jacques A. Greenberg, Maureen D. Moore, Jessica W. Thiesmeyer, Caitlin E. Egan, Yeon Joo Lee, Paul Christos, Rasa Zarnegar, Toni Beninato, Thomas J. Fahey, Brendan M. Finnerty
Summary: The prognosis of patients with coexisting papillary thyroid cancer (PTC) and anaplastic thyroid carcinoma (ATC) depends on the presence of aggressive clinicopathologic features and lies between that of PTC and ATC. Adjuvant radioactive iodine (RAI) and external beam radiation therapy (EBRT) may improve survival, even after complete surgical resection.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Andreas Machens, Kerstin Lorenz, Frank Weber, Henning Dralle
Summary: This study identified lymph node metastasis and patient age over 60 as important risk factors for distant metastasis in various types of thyroid cancer. Recognizing risk patterns of early distant metastasis could provide opportunities for early surgical intervention.
HORMONE AND METABOLIC RESEARCH
(2022)
Review
Oncology
Kaushal Parikh, Lizza E. L. Hendriks, Paolo Bironzo, Jordi Remon
Summary: Malignant pleural mesothelioma is a rare and aggressive thoracic malignancy with poor prognosis, but the recent approval of immune checkpoint inhibitors has brought hope for treatment. However, there are still unresolved challenges, such as determining the best upfront immune approach and utilizing predictive biomarkers.
CANCER TREATMENT REVIEWS
(2021)
Review
Immunology
Rui Rui, Liqun Zhou, Shiming He
Summary: Immunotherapy has revolutionized cancer treatment, with ongoing advancements. The aim of cancer immunotherapy is to activate the host immune system to fight against malignant tumors. Tumor infiltrating leukocytes play a role in tumor microenvironment and their interaction with tumor cells influences tumor progression. Various immunotherapies, such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer, have shown promising efficacy. This review summarizes the recent research progress in tumor immunotherapy, including molecular mechanisms, clinical effects, and limitations.
FRONTIERS IN IMMUNOLOGY
(2023)